Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone-cartilage interface and subchondral bone marrow

Arthritis and Rheumatism

Volumn 54, Issue 6, 2006, Pages 1805-1813

  Appel, Heiner ^a   Kuhne, Maren ^a   Spiekermann, Simone ^a   Köhler, Dorothee ^a   Zacher, Josef ^b   Stein, Harald ^a   Sieper, Joachim ^a   Loddenkemper, Christoph ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Helios Kliniken Wismarsche S   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGIOGENESIS; ANKYLOSING SPONDYLITIS; ARTICLE; CARTILAGE DEGENERATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COXITIS; FEMALE; FEMUR HEAD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MALE; MICROVASCULATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOCLAST; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TOTAL HIP PROSTHESIS;

ADULT; AGED; ARTHRITIS; ARTHRITIS, RHEUMATOID; BONE MARROW; CARTILAGE, ARTICULAR; FEMALE; FEMUR HEAD; HIP JOINT; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OSTEOARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 33745055952     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21907     Document Type: Article

References (51)

1. Poole AR. The histopathology of ankylosing spondylitis: are there unifying hypotheses? Am J Med Sci 1998;316:228-33.
2. Maksymowych WP. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol 2000;27:2295-301.
3. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998;352:1137-40.
4. Ball J. Pathology and pathogenesis. In: Moll JM, editor. Ankylosing spondylitis. Edinburgh: Churchill Livingstone; 1980. p. 96-112.
5. McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998;41:694-700.
6. Cruickshank B. Pathology of ankylosing spondylitis. Clinical Orthop Relat Res 1971;74:43-58.
7. Bywaters EG, Olsen E. A case of early ankylosing spondylitis with fatal secondary amyloidosis: demonstrated at the Royal Postgraduate Medical School. BMJ 1968;2:412-6.
8. Francois RJ, Gardner DL, Degrave EJ, Bywaters EG. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000;43:2011-24.
9. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
10. Savill DL. The manubrio-sternal joint in ankylosing spondylitis. J Bone Joint Surg Br 1951;33:56-64.
11. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45.
12. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59:135-40.
13. Golder W, Karberg K, Sieper J. Fluoroscopy-guided application of corticosteroids for local control of manubriosternal joint pain in patients with spondyloarthropathies. Clin Rheumatol 2004;23:481-4.
14. Lambert RG, Dhillon SS, Jhangri GS, Sacks J, Sacks H, Wong B, et al. High prevalence of symptomatic enthesopathy of the shoulder in ankylosing spondylitis: deltoid origin involvement constitutes a hallmark of disease. Arthritis Rheum 2004;51:681-90.
15. Laloux L, Voisin MC, Allain J, Martin N, Kerboull L, Chevalier X, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001;60:316-21.
16. Calin A, Elswood J. The relationship between pelvic, spinal and hip involvement in ankylosing spondylitis: one disease process or several? Br J Rheumatol 1988;27:393-5.
17. Sweeney S, Gupta R, Taylor G, Calin A. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol 2001;28:1862-6.
18. Schlingemann RO, Rietveld FJ, de Waal RM, Bradley NJ, Skene AI, Davies AJ, et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990;62:690-6.
19. Nakajima T, Watanabe S, Sato Y, Kameya T, Hirota T, Shimosato Y. An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol 1982;6:715-27.
20. Goldberg AF, Barka T. Acid phosphatase activity in human blood cells [letter]. Nature 1962;195:297.
21. Filgueira L. Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols. J Histochem Cytochem 2004;52:411-4.
22. Mohr W. The pathogenesis of joint destruction in chronic polyarthritis. Radiologe 1996;36:593-9. In German.
23. Giant TT, Mikecz K, Arzoumanian A, Poole AR. Proteoglycan-induced arthritis in BALB/c mice: clinical features and histopathology. Arthritis Rheum 1987;30:201-12.
24. Mikecz K, Glant TT, Poole AR. Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthritis Rheum 1987;30:306-18.
25. Zhang Y, Guerassimov A, Leroux JY, Cartman A, Webber C, Lalic R, et al. Induction of arthritis in BALB/c mice by cartilage link protein: involvement of distinct regions recognized by T and B lymphocytes. Am J Pathol 1998;153:1283-91.
26. Guerassimov A, Zhang Y, Banerjee S, Cartman A, Leroux JY, Rosenberg LC, et al. Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate. Arthritis Rheum 1998;41:1019-25.
27. Zou J, Zhang Y, Thiel A, Rudwaleit M, Shi SL, Radbruch A, Poole R, et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology 2003;42:846-55.
28. Zou J, Appel H, Rudwaleit M, Thiel A, Sieper J. Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis 2005;64:722-9.
29. Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum 2005;52:892-901.
30. Bardos T, Szabo Z, Czipri M, Vermes C, Tunyogi-Csapo M, Urban RM, et al. A longitudinal study on an autoimmune murine model of ankylosing spondylitis. Ann Rheum Dis 2005;64:981-7.
31. Paleolog EM. Angiogenesis: a critical process in the pathogenesis of RA-a role for VEGF? Br J Rheumatol 1996;35:917-9.
32. Baeten D, Demetter P, Cuvelier C, Van Den Bosch F, Kruithof E, Van Damme N, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000;59:945-53.
33. Baeten D, De Keyser F. The histopathology of spondyloarthropathy. Curr Mol Med 2004;4:1-12.
34. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005;64:529-36.
35. Espinoza LR, Vasey FB, Espinoza CG, Bocanegra TS, Germain BF. Vascular changes in psoriatic synovium: a light and electron microscopic study. Arthritis Rheum 1982;25:677-84.
36. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, FitzGerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993;36:893-900.
37. Goldberger C, Dulak J, Duftner C, Weidinger F, Falkenbach A, Schirmer M. Vascular endothelial growth factor (VEGF) in ankylosing spondylitis: a pilot study. Wien Med Wochenschr 2002;152:223-5.
38. Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003;132:158-62.
39. Pufe T, Petersen W, Tillmann B, Mentlein R. The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum 2001;44:1082-8.
40. De Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2000;43:2056-63.
41. Sone H, Kawakami Y, Sakauchi M, Nakamura Y, Takahashi A, Shimano H, et al. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001;281:562-8.
42. Miotla J, Mackiewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000;80:1195-205.
43. Pap T, Distler O. Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum 2005;52:1346-8.
44. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
45. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-51.
46. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, and the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
47. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
48. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
49. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
50. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31.
51. Deckers MM, Karperien M, van der Bent C, Yamashita T, Papapoulos SE, Lowik CW. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 2000;141:1667-74.